

US00D593613S

(12) **United States Design Patent**
Langan et al.

(10) **Patent No.:** **US D593,613 S**
(45) **Date of Patent:** **** Jun. 2, 2009**

(54) **DRUG ADMINISTRATION SAFETY LABEL**
(75) Inventors: **Amy E. Langan**, Glenview, IL (US);
Richard J. Kruzynski, Long Grove, IL (US);
John A. Kollar, Northbrook, IL (US);
Patricia L. Miyake, Mundelein, IL (US);
Monique L. Kruk, Burlington, WI (US);
Mark F. Wagner, Gurnee, IL (US)

5,924,561 A	7/1999	Baumgartner et al.	
6,089,611 A *	7/2000	Blank	283/67
D432,176 S *	10/2000	Stevens et al.	D20/22
6,299,213 B1 *	10/2001	Souparis	283/81
D453,529 S *	2/2002	Roth	D19/10
D412,131 S	5/2003	Takahashi et al.	
D500,524 S *	1/2005	Stewart et al.	D20/27
D522,065 S	5/2006	Greenstein	
D550,287 S	9/2007	Smart et al.	
7,311,205 B2	12/2007	Adler et al.	
D588,200 S *	3/2009	Langan et al.	D20/27
2007/0029788 A1	2/2007	Adler	
2007/0252378 A1	11/2007	Chambers	

(73) Assignee: **Pharmedium Services, LLC**, Lake Forest, IL (US)

(**) Term: **14 Years**

(21) Appl. No.: **29/332,178**

(22) Filed: **Feb. 10, 2009**

Related U.S. Application Data

(62) Division of application No. 29/298,328, filed on Dec. 3, 2007, now Pat. No. Des. 588,200.

(51) **LOC (9) Cl.** **19-08**
(52) **U.S. Cl.** **D20/27**
(58) **Field of Classification Search** D20/10,
D20/11, 13, 22-24, 27, 99; 40/124.01, 124.02,
40/124.04, 299.01, 310, 325, 360, 326, 538,
40/541, 584, 594, 600, 630, 638; D19/1,
D19/9, 10; 206/63.3, 534; 283/56, 67, 71,
283/81; 359/2; 428/40.1, 40.2, 42.3, 914
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,065,343 A	12/1977	Stumpe	
4,815,768 A *	3/1989	Applebaum et al.	283/67
D311,423 S	10/1990	DeSantis	
5,426,520 A *	6/1995	Kakae et al.	359/2
D386,212 S	11/1997	Lambert	

OTHER PUBLICATIONS

Syringe label for Atropine sulfate, known prior to Dec. 3, 2007, 1 page.

(Continued)

Primary Examiner—Janice E Seeger
Assistant Examiner—Mary Ann Calabrese
(74) *Attorney, Agent, or Firm*—K&L Gates, LLP


(57) **CLAIM**

The ornamental design for a drug administration safety label, as shown and described.

DESCRIPTION

FIG. 1 is a top plan view of an embodiment of a drug administration safety label of our new design.
FIG. 2 is a top plan view of a second embodiment of a drug administration safety label of our new design.
FIG. 3 is a top plan view of a third embodiment of a drug administration safety label of our new design; and,
FIG. 4 is a top plan view of a fourth embodiment of a drug administration safety label of our new design.
In the drawings, the broken lines represent environmental structure forming no part of the claimed design.

1 Claim, 4 Drawing Sheets



OTHER PUBLICATIONS

Label for alcohol preps, known prior to Dec. 3, 2007, 1 page.

IV bag label for 0.9% Sodium Chloride, known prior to Dec. 3, 2007, 1 page.

Syringe label for Labetalol Hydrochloride, known prior to Dec. 3, 2007, 1 page.

Label for drug vial for 0.9% Sodium Chloride, known prior to Dec. 3, 2007, 1 page.

Syringe label for Calcium Chloride, known prior to Dec. 3, 2007, 1 page.

Drug delivery device label for Phenylephrine, known prior to Dec. 3, 2007, 1 page.

Label for drug vial for Phenylephrine, known prior to Dec. 3, 2007, 1 page.

IV bag label for Fentanyl and Ropivacaine, known prior to Dec. 3, 2007, 1 page.

* cited by examiner

FIG. 1




FIG. 2




FIG. 3




FIG. 4

